{"analyses":[{"groupDescription":"Null Hypothesis: There is no difference in response rate between 1q21 amplified and 1q21 NOT amplified","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.01","statisticalMethod":"Log Rank","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.0"},{"groupId":"OG001","value":"69.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"20"}],"units":"Participants"}],"description":"Percentage of participants who did not have any of the following events: Death, Disease progression, Relapse, Cardiovascular accidents, Deep vein thrombosis, Pulmonary embolism, Fracture, Acute renal failure, Nervous system disorders 2 years after Day 1 Cycle 1 of bortezomib, doxorubicin and dexamethasone (PAD).","groups":[{"description":"Participants without 1q21 amplification. Four 21-day cycles of bortezomib 1.3 mg/m2 intravenous (IV) on Days 1, 4, 8 and 11; plus doxorubicin 20 mg/m2 IV on Days 1 and 4; and dexamethasone 20 mg oral on Days 1, 2, 4, 5, 8, 9, 11 and 12.","id":"OG000","title":"1q21 Not Amplified"},{"description":"Participants with 1q21 amplification. Four 21-day cycles of bortezomib 1.3 mg/m2 intravenous (IV) on Days 1, 4, 8 and 11; plus doxorubicin 20 mg/m2 IV on Days 1 and 4; and dexamethasone 20 mg oral on Days 1, 2, 4, 5, 8, 9, 11 and 12.","id":"OG001","title":"1q21 Amplified"}],"paramType":"NUMBER","populationDescription":"Intent-to-treat (ITT) population - All participants who were screened and received at least one dose of PAD","reportingStatus":"POSTED","timeFrame":"2 years after Day 1 Cycle 1 of PAD","title":"Event Free Survival (EFS)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}